<

PHARNEXT (EPA:ALPHA) Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

Transparency directive : regulatory news

24/08/2023 08:30



Other stories

28/04/2024 20:00
28/04/2024 21:00
28/04/2024 19:12
28/04/2024 20:35
28/04/2024 23:58
28/04/2024 13:56
28/04/2024 18:54
28/04/2024 13:36
28/04/2024 13:48
28/04/2024 18:57
28/04/2024 19:10
28/04/2024 19:18
28/04/2024 13:08
29/04/2024 01:01
28/04/2024 20:01
28/04/2024 20:55
28/04/2024 16:41
28/04/2024 19:47
27/04/2024 13:12
28/04/2024 13:36
28/04/2024 07:08
27/04/2024 01:21
28/04/2024 08:56
28/04/2024 07:48
28/04/2024 18:56
28/04/2024 20:02
28/04/2024 22:08
29/04/2024 00:36
28/04/2024 21:20
28/04/2024 21:57
28/04/2024 22:44
27/04/2024 14:00
28/04/2024 09:42
28/04/2024 11:41
28/04/2024 12:18
28/04/2024 08:51
27/04/2024 13:26
28/04/2024 23:41